ICR publications

Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial.

26 July 2026

Salvage Neck Dissection in Recurrent Head and Neck Squamous Cell Carcinoma After Primary Radiotherapy (RESCUE): An IReC Multicentre Consecutive Cohort Study.

14 July 2026

ASO Visual Abstract: The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC-A UK Single-Centre Experience and the Implications for Surgical Management.

01 July 2026

The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC: A UK Single-Centre Experience and the Implications for Surgical Management.

01 July 2026

Interrogating the immune landscape of microsatellite stable RAS-mutated colon cancer.

01 July 2026

Cytokine release symptoms rather than syndromes: a call for granular reporting of cytokine-related adverse events in clinical trials

01 July 2026

Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck.

01 July 2026

Evaluation of a point of care prostate-specific antigen blood test on a mobile outreach service.

01 July 2026

Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer.

24 June 2026

Expanding the human proteome with microproteins and peptideins.

18 June 2026

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma.

15 June 2026

Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.

05 June 2026

�ԹϺ��

ICR publications

ICR ImmNet publications feed

Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial.

Salvage Neck Dissection in Recurrent Head and Neck Squamous Cell Carcinoma After Primary Radiotherapy (RESCUE): An IReC Multicentre Consecutive Cohort Study.

ASO Visual Abstract: The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC-A UK Single-Centre Experience and the Implications for Surgical Management.

The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC: A UK Single-Centre Experience and the Implications for Surgical Management.

Interrogating the immune landscape of microsatellite stable RAS-mutated colon cancer.

Cytokine release symptoms rather than syndromes: a call for granular reporting of cytokine-related adverse events in clinical trials

Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck.

Evaluation of a point of care prostate-specific antigen blood test on a mobile outreach service.

Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer.

Expanding the human proteome with microproteins and peptideins.

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma.

Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.

Faculty of Medicine

Find us on social media

�ԹϺ���

ICR publications

ICR ImmNet publications feed

Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial.

Salvage Neck Dissection in Recurrent Head and Neck Squamous Cell Carcinoma After Primary Radiotherapy (RESCUE): An IReC Multicentre Consecutive Cohort Study.

ASO Visual Abstract: The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC-A UK Single-Centre Experience and the Implications for Surgical Management.

The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC: A UK Single-Centre Experience and the Implications for Surgical Management.

Interrogating the immune landscape of microsatellite stable RAS-mutated colon cancer.

Cytokine release symptoms rather than syndromes: a call for granular reporting of cytokine-related adverse events in clinical trials

Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck.

Evaluation of a point of care prostate-specific antigen blood test on a mobile outreach service.

Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer.

Expanding the human proteome with microproteins and peptideins.

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma.

Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.

Faculty of Medicine

Find us on social media

�ԹϺ��